Talks
Disparities in Occurrence of Cancer Due to Different Treatment Modalities in Rheumatoid Arthritis Patients
Presentation Type
Oral Presentation
Discipline Track
Community/Public Health
Abstract Type
Research/Clinical
Abstract
Rheumatoid arthritis(RA)is inflammatory disorder characterised by ongoing inflammatory responses which involve multiple joints and is the leading cause of increased morbidity and mortality. Malignant lymphoma, infections and cardio vascular diseases tend to increase severity of RA. The disease itself and its treatment can contribute in increasing overall risk of cancer in the RA patients. Cancer management in rheumatic patients pose a big challenge as it requires several considerations due to maintenance of these patients on immunosuppressive therapies. Given the fact that anti-cancer agents in low dose are used to treat the ongoing inflammation in RA patients, however, both beneficial and adverse responses are observed. Treatment of RA with disease modifying anti rheumatic agents (DMARDs) can increase the risk of cancer as studies have found association between augmented tumorigenesis and DMARDs. Methotrexate (MTX) considered as gold standard for treating RA might be associated with lymphoproliferative disorder(MTX-LPD) while salicylates could reduce the risk of malignancies in RA patients. RA patients are also prone for reoccurrence of cancers with usage of different treatment modalities. In this study we aim to address disparities in the occurrence of various cancers with respect to different treatment modalities in rheumatoid arthritis patients.
Academic/Professional Position
Faculty
Recommended Citation
Gupta, Varsha, "Disparities in Occurrence of Cancer Due to Different Treatment Modalities in Rheumatoid Arthritis Patients" (2023). Research Symposium. 53.
https://scholarworks.utrgv.edu/somrs/theme1/track1/53
Disparities in Occurrence of Cancer Due to Different Treatment Modalities in Rheumatoid Arthritis Patients
Rheumatoid arthritis(RA)is inflammatory disorder characterised by ongoing inflammatory responses which involve multiple joints and is the leading cause of increased morbidity and mortality. Malignant lymphoma, infections and cardio vascular diseases tend to increase severity of RA. The disease itself and its treatment can contribute in increasing overall risk of cancer in the RA patients. Cancer management in rheumatic patients pose a big challenge as it requires several considerations due to maintenance of these patients on immunosuppressive therapies. Given the fact that anti-cancer agents in low dose are used to treat the ongoing inflammation in RA patients, however, both beneficial and adverse responses are observed. Treatment of RA with disease modifying anti rheumatic agents (DMARDs) can increase the risk of cancer as studies have found association between augmented tumorigenesis and DMARDs. Methotrexate (MTX) considered as gold standard for treating RA might be associated with lymphoproliferative disorder(MTX-LPD) while salicylates could reduce the risk of malignancies in RA patients. RA patients are also prone for reoccurrence of cancers with usage of different treatment modalities. In this study we aim to address disparities in the occurrence of various cancers with respect to different treatment modalities in rheumatoid arthritis patients.